Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 19 (1), 1-48

Korean Practice Guideline for Gastric Cancer 2018: An Evidence-based, Multi-disciplinary Approach


Korean Practice Guideline for Gastric Cancer 2018: An Evidence-based, Multi-disciplinary Approach

Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. J Gastric Cancer.

Erratum in

Conflict of interest statement

Conflict of Interest: No potential conflict of interest relevant to this article was reported.


Fig. 1
Fig. 1. Overall treatment algorithm.
Diff. = differentiated; Undiff. = undifferentiated.
Fig. 2
Fig. 2. Treatment algorithm for endoscopic resection.
Diff. = differentiated; Undiff. = undifferentiated; ESD = endoscopic submucosal dissection.
Fig. 3
Fig. 3. (A) Treatment algorithm for resectable gastric adenocarcinoma. (B) Treatment algorithm for resectable esophagogastric junction adenocarcinoma.
ESD = endoscopic submucosal dissection; LND = lymph node dissection.
Fig. 4
Fig. 4. Treatment algorithm for palliative systemic therapy.
HER2 = human epidermal growth factor receptor 2; XP = capecitabine and cisplatin; FP = fluorouracil and cisplatin; IHC = immunohistochemistry. *HER2 IHC 3+ or IHC 2+ and in situ hybridization-positive; Evaluation of patient performance status, comorbidities, and organ function.

Similar articles

See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles


    1. Jung KW, Won YJ, Kong HJ, Lee ES Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50:303–316. - PMC - PubMed
    1. Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104. - PMC - PubMed
    1. The Korean Gastric Cancer Association. Korean guideline for gastric cancer. J Korean Gastric Cancer Assoc. 2004;4:286–293.
    1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. - PMC - PubMed
    1. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408–414. - PubMed